Jci_page_head_homepage_01 Jci_page_head_homepage_02
David S. Ziegler, Renee D. Wright, Santosh Kesari, Madeleine E. Lemieux, Mary A. Tran, Monish Jain, Leigh Zawel, Andrew L. Kung
Published in Volume 118, Issue 9
J Clin Invest. 2008; 118(9):3109–3122 doi:10.1172/JCI34120
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Jci0834120
Figure 6
AMN107 and LBW242 combine to inhibit the growth of intracranial LN827 orthografts and primary human glioblastoma neurospheres in vitro and in vivo.

(A) Bioluminescent images from control and treated animals at the start and end of a 15-day treatment with the indicated doses of LBW242 and/or AMN107. (B) Tumor burden was assessed by serial bioluminescence imaging and expressed relative to the start of treatment. Data are mean values ± SEM, n = 6 animals per group. (C) Primary human glioma neurospheres were derived from 2 different patients (BT69, white bars; BT79, black bars) and were treated with imatinib and/or LBW242. (D) Total neurosphere numbers were counted and photographed 10 days after plating, with data expressed as relative mean ± SD of triplicates. (E) Tumor neurospheres treated for 72 hours with imatinib, AMN107 (AMN), and/or LBW242 (LBW) were lysed and activated caspase-3 was assessed by immunoblot. (F) Kaplan-Meier survival curves for mice implanted with primary human glioma orthografts. Mice were treated for 12 consecutive days with vehicle, AMN107, LBW242, or a combination of AMN107 and LBW242, with treatments beginning 12 days after implant. *P = 0.01, combination versus all other groups, for experimental day 60 and all time points thereafter.